New Updated AASLD Guidelines includes Harvoni and new AbbVie drugs
skewedButNotBroken said
Dec 21, 2014
If you sign up for tweets from Dr. Robert Gish, you will be notified anytime something major happens in the world of hep c: https://twitter.com/RobertGish
-- Edited by skewedButNotBroken on Monday 22nd of December 2014 02:19:43 AM
Beacon said
Dec 21, 2014
Josh,
There was no grand announcement that the AASLD had updated their guidelines but I
knew it supposed to be sometime this month. It looks like here in the USA that
after the publishing of these guidelines, the final nail has been put in
interferon's casket, but ribavirin is still useful.
Josh Haynie said
Dec 21, 2014
ca-ching ... nice find BEACON... i tried clicking on the more text links and it blocked me :( so i found this http://www.hcvguidelines.org/
password sumthin or other pantheon.....
and this http://www.hcvguidelines.org/node/71
anyway thanks for finding that :)
Beacon said
Dec 21, 2014
These are the new AASLD guidelines posted:
Compensated Cirrhosis Genotype 1A
Three options with similar efficacy in general are recommended for treatment-naive patients with HCV genotype 1a infection (listed in alphabetic order; see text).
Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) for 12 weeks* is recommended for treatment-naive patients with HCV genotype 1a infection. *see text for further detail on length of treatment
Rating: Class I, Level A
Daily fixed-dose combination of paritaprevir (150 mg)/ritonavir (100 mg)/ombitasvir (25 mg) plus twice-daily dosed dasabuvir (250 mg) and weight-based RBV (1000 mg [<75 kg] to 1200 mg [>75 mg]) for 12 weeks (no cirrhosis) or 24 weeks (cirrhosis [see also Cirrhosis Section]) is recommended for treatment-naive patients with HCV genotype 1a infection.
Rating: Class I, Level A
Daily sofosbuvir (400 mg) plus simeprevir (150 mg) with or without weight-based RBV (1000 mg [<75 kg] to 1200 mg [>75 kg]) for 12 weeks (no cirrhosis) or 24 weeks (cirrhosis [see also Cirrhosis Section]) is recommended for treatment-naive patients with HCV genotype 1a infection.
Genotype 1B
Three options with similar efficacy in general are recommended for treatment-naive patients with HCV genotype 1b infection (listed in alphabetic order; see text).
Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) for 12 weeks* is recommended for treatment-naive patients with HCV genotype 1b infection. *see text for further detail on length of treatment
Rating: Class I, Level A
Daily fixed-dose combination of paritaprevir (150 mg)/ritonavir (100 mg)/ombitasvir (25 mg) plus twice-daily dosed dasabuvir (250 mg) for 12 weeks is recommended for treatment-naive patients with HCV genotype 1b infection.Rating: Class I, Level AThe addition of weight-based RBV (1000 mg [<75kg] to 1200 mg [>75 mg]) is recommended in patients with cirrhosis. (See also Cirrhosis Section)
Rating: Class I, Level A
Daily sofosbuvir (400 mg) plus simeprevir (150 mg) for 12 weeks (no cirrhosis) or 24 weeks (cirrhosis [See also Cirrhosis Section]) is recommended for treatment-naive patients with HCV genotype 1b infection
Anyway I didn't want this to be too long so all the other updated treatment guidelines are posted on their website.
p.s. don't bother to click on any links in this post as they don't work.
-- Edited by Beacon on Monday 22nd of December 2014 01:47:45 AM
If you sign up for tweets from Dr. Robert Gish, you will be notified anytime something major happens in the world of hep c: https://twitter.com/RobertGish
-- Edited by skewedButNotBroken on Monday 22nd of December 2014 02:19:43 AM
Josh,
There was no grand announcement that the AASLD had updated their guidelines but I
knew it supposed to be sometime this month. It looks like here in the USA that
after the publishing of these guidelines, the final nail has been put in
interferon's casket, but ribavirin is still useful.
ca-ching ... nice find BEACON... i tried clicking on the more text links and it blocked me :( so i found this http://www.hcvguidelines.org/
password sumthin or other pantheon.....
and this http://www.hcvguidelines.org/node/71
anyway thanks for finding that :)
These are the new AASLD guidelines posted:
Compensated Cirrhosis Genotype 1A
Three options with similar efficacy in general are recommended for treatment-naive patients with HCV genotype 1a infection (listed in alphabetic order; see text).
Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) for 12 weeks* is recommended for treatment-naive patients with HCV genotype 1a infection.
*see text for further detail on length of treatment
Rating: Class I, Level A
Daily fixed-dose combination of paritaprevir (150 mg)/ritonavir (100 mg)/ombitasvir (25 mg) plus twice-daily dosed dasabuvir (250 mg) and weight-based RBV (1000 mg [<75 kg] to 1200 mg [>75 mg]) for 12 weeks (no cirrhosis) or 24 weeks (cirrhosis [see also Cirrhosis Section]) is recommended for treatment-naive patients with HCV genotype 1a infection.
Rating: Class I, Level A
Daily sofosbuvir (400 mg) plus simeprevir (150 mg) with or without weight-based RBV (1000 mg [<75 kg] to 1200 mg [>75 kg]) for 12 weeks (no cirrhosis) or 24 weeks (cirrhosis [see also Cirrhosis Section]) is recommended for treatment-naive patients with HCV genotype 1a infection.
Genotype 1B
Three options with similar efficacy in general are recommended for treatment-naive patients with HCV genotype 1b infection (listed in alphabetic order; see text).
Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) for 12 weeks* is recommended for treatment-naive patients with HCV genotype 1b infection.
*see text for further detail on length of treatment
Rating: Class I, Level A
Daily fixed-dose combination of paritaprevir (150 mg)/ritonavir (100 mg)/ombitasvir (25 mg) plus twice-daily dosed dasabuvir (250 mg) for 12 weeks is recommended for treatment-naive patients with HCV genotype 1b infection. Rating: Class I, Level A The addition of weight-based RBV (1000 mg [<75kg] to 1200 mg [>75 mg]) is recommended in patients with cirrhosis. (See also Cirrhosis Section)
Rating: Class I, Level A
Daily sofosbuvir (400 mg) plus simeprevir (150 mg) for 12 weeks (no cirrhosis) or 24 weeks (cirrhosis [See also Cirrhosis Section]) is recommended for treatment-naive patients with HCV genotype 1b infection
Anyway I didn't want this to be too long so all the other updated treatment guidelines are posted on their website.
p.s. don't bother to click on any links in this post as they don't work.
-- Edited by Beacon on Monday 22nd of December 2014 01:47:45 AM